Adjuvant BRAF and MEK Inhibition for Melanoma: ' Impressive ' Adjuvant BRAF and MEK Inhibition for Melanoma: ' Impressive '

New at ESMO 2017, adjuvant dabrafenib/trametinib in stage III melanoma shows ' impressive ' results in relapse-free survival.Medscape Oncology

Source: Medscape Today Headlines - October 31, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news